• Innovative method to improve cancer immunotherapy

    The Preclinical Imaging and Radiopharmacy Department of the University Hospital Tübingen and ImaginAb, a global market leading biotech company, are cooperating in the field of cancer immunotherapy making Tübingen Europe's first center for the production of radiolabeled CD8 minibodies.

    Read more

  • TheranosticValleySTR project outline reaches 2nd round of BMBF "Clusters4Future" call

    TheranosticValleySTR (STR= Research and Economic Region Stuttgart, Tübingen, Reutlingen) represents the concept for an innovative future cluster to fundamentally improve diagnosis and therapy of cancer, infectious and neurological diseases. The main drivers of this concept, the University of Tübingen, MPI Tübingen-Stuttgart and the NMI Reutlingen, are among the 15 chosen conceputal clusters (out of 117 applicants) to hand in a full concept. 

    Read more